Aytu Biopharma (AYTU) Cash from Operations Growth (1y) (2011 - 2026)
Aytu Biopharma (AYTU) Cash from Operations Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 61.90% |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | -22.14% |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | 8.20% |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 0.46% |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | -27.49% |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 125.00% |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | 425.00% |
| 10 | Aytu Biopharma | 21.45 Mn | -5.27 Mn | 7.60 Mn | 35.21% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 35.21% |
| Dec 31, 2025 | 26.51% |
| Sep 30, 2025 | 48.07% |
| Jun 30, 2025 | 455.71% |
| Mar 31, 2025 | -2,441.34% |
| Dec 31, 2024 | 2,251.85% |
| Sep 30, 2024 | -463.98% |
| Jun 30, 2024 | -108.41% |
| Mar 31, 2024 | 91.28% |
| Dec 31, 2023 | 94.57% |
| Sep 30, 2023 | 97.68% |
| Jun 30, 2023 | 232.08% |
| Mar 31, 2023 | 68.05% |
| Dec 31, 2022 | 71.77% |
| Sep 30, 2022 | -139.47% |
| Jun 30, 2022 | -12.62% |
| Dec 31, 2021 | -203.16% |
| Sep 30, 2021 | 52.50% |
| Jun 30, 2021 | 19.14% |
| Dec 31, 2020 | 52.34% |